VCYT - Latest News
Veracyte, Inc. (VCYT), operates in Healthcare / Medical - Diagnostics & Research, trades on NASDAQ.
Market capitalization stands near $3.29B. Trailing twelve-month P/E ratio is 28.70. Beta to the broader market is 1.94.
The article list below shows the most recent VCYT headlines from major financial news vendors. For options traders, the most actionable items are earnings releases, analyst rating changes, M&A activity, and regulatory filings - each can drive a meaningful repricing of implied volatility and shift dealer hedging flow. Pair the news context with the implied-volatility skew and gamma exposure views to see whether the options market has already priced in the headline.
Recent VCYT Headlines
Bank of America Corp DE Grows Stock Position in Veracyte, Inc. $VCYT
defenseworld.net - Aug 13, 2026
Bank of America Corp DE grew its position in shares of Veracyte, Inc. (NASDAQ: VCYT) by 14.
Veracyte: Diagnostics With Favorable Economics
seekingalpha.com - Aug 10, 2026
Veracyte's core tests are Decipher and Afirma. Both of these tests are producing double-digit growth with improving margins.
Veracyte: Core Growth Funds Prosigna And TrueMRD
seekingalpha.com - Aug 9, 2026
Veracyte (VCYT) is evolving into a self-funded cancer diagnostic platform, leveraging clinical evidence, specialist relationships, and reimbursement i
Veracyte, Inc. (VCYT) Q2 2026 Earnings Call Transcript
seekingalpha.com - Jul 31, 2026
Veracyte, Inc.
Veracyte (VCYT) Q2 Earnings and Revenues Surpass Estimates
zacks.com - Jul 30, 2026
Veracyte (VCYT) came out with quarterly earnings of $0. 54 per share, beating the Zacks Consensus Estimate of $0.
How News Affects VCYT Options Pricing
Headlines and scheduled events drive implied volatility in two distinct ways. Pre-event, IV typically inflates as uncertainty about the outcome rises; this is the implied-volatility expansion that creates the long-vol setup. Post-event, IV typically contracts sharply as uncertainty resolves; this is IV crush, which makes premium-selling structures profitable when they survive the underlying move. The size of the crush depends on how stretched pre-event IV is relative to the realized move. Track VCYT's implied vs realized volatility over the news cycle to size pre-event vs post-event positioning. For ticker-level dealer positioning context, the gamma exposure view shows whether dealers are positioned to amplify or dampen post-news moves.
Frequently asked VCYT news questions
- What is the latest VCYT news headline?
- The most recent VCYT headline (Aug 13, 2026) is "Bank of America Corp DE Grows Stock Position in Veracyte, Inc. $VCYT". The five most recent stories with summaries and publication times are listed above, sourced from major financial news vendors.
- How fresh is the VCYT news on this page?
- News rows refresh roughly every 30 minutes during the trading day. The five most recent headlines are listed in publication-time order. Press releases from the company itself typically appear within minutes of the wire release; third-party reporting may lag by 30-60 minutes depending on the source.
- What VCYT news moves options pricing?
- Three categories move single-name IV most aggressively: scheduled earnings releases (priced into pre-event IV, crushed post-event), unscheduled M&A or strategic announcements (rapid IV expansion, slower decay), and regulatory or legal events (drug-trial readouts, antitrust filings, FDA approvals). Routine news flow (analyst commentary, sector rotation) typically does not move IV meaningfully unless it triggers a cluster of rating changes.
- How can I track unusual VCYT options activity related to news?
- Unusual options activity often precedes news by hours to days; the canonical signals are volume substantially above the trailing average concentrated in a small number of strikes, atypical put/call skew, and aggressive execution (at-the-ask sweeps or block prints). Cross-reference the per-ticker gamma-exposure and volume-history pages with the news flow above to triangulate informed vs uninformed flow.